STOCK TITAN

Wellspect HealthCare Expands Surity™ Portfolio in the U.S. with Surity™ Male External Catheter for Urinary Incontinence Care

(Moderate)
(Neutral)
Tags

Wellspect HealthCare (NASDAQ:XRAY) launched the Surity™ Male External Catheter in the U.S. on April 30, 2026, expanding its Surity™ continence portfolio already including a female catheter and an upcoming Surity™ Urinary Management System.

The device is non‑invasive, suitable for up to 24 hours wear, features a see‑through design and slim profile, and is available now for home purchase at www.surity.care; institutional availability is described as coming soon.

Loading...
Loading translation...

Positive

  • U.S. commercial launch of Surity Male External Catheter
  • Non‑invasive design rated for up to 24 hours wear
  • See‑through, slim profile and skin‑friendly materials for ease of placement
  • Direct home purchase available now at www.surity.care

Negative

  • No pricing, reimbursement, or sales guidance disclosed
  • Institutional availability timing is unspecified ('coming soon')

News Market Reaction – XRAY

+2.35%
+2.35% Session close to close

In the Apr 30 session, XRAY gained 2.35%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights continued expansion of the Surity portfolio into male urinary incontine...
Analysis

This announcement highlights continued expansion of the Surity portfolio into male urinary incontinence, targeting a population of more than 13 million Americans with a non-invasive external catheter designed for up to 24 hours of wear. It follows earlier launches in female incontinence and precedes a broader urinary management system. In context of recent clinical innovations and restructuring-driven guidance, investors may watch for future disclosures connecting this product family to revenue growth and margin trends.

Key Figures

Affected Americans: more than 13 million Wear duration: 24 hours
2 metrics
Affected Americans more than 13 million Severe urinary incontinence prevalence in the U.S.
Wear duration 24 hours Maximum wear time for Surity Male External Catheter

Historical Context

5 past events · Latest: Apr 22 (Neutral)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Apr 22 Earnings call scheduling Neutral -2.2% Announcement of timing for Q1 2026 results call and webcast.
Mar 09 Clinical device clearance Positive +0.5% FDA clearance of MAGNETOM Free.Max Dental Edition after supporting clinical trial.
Mar 03 Conference participation Neutral +1.1% Planned presentation at Leerink Partners Global Healthcare Conference 2026.
Feb 26 Earnings and outlook Positive +15.5% Q4 and FY 2025 results plus 2026 guidance and restructuring program details.
Feb 24 Board changes Positive -2.6% Appointment of two new directors and long‑tenured director’s planned retirement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Price has generally moved in the same direction as the tone of prior news, with the main divergence occurring on board appointment news that coincided with a price decline.

Recent Company History

Over the past few months, XRAY’s news flow has covered earnings, clinical innovation, governance, and investor events. On Feb 26, 2026, Q4 2025 results and a $3.5B–$3.6B FY 2026 sales outlook coincided with a 15.5% gain. FDA clearance of a dental‑dedicated MRI on Mar 9, 2026 saw a modest positive reaction. Board refresh news on Feb 24, 2026 was followed by a decline. Recent conference announcements in March and April had relatively small price moves, framing today’s product launch within a steady flow of operational updates.

Key Terms

urinary incontinence, male external catheter, urinary tract infections, meta-analysis
4 terms
urinary incontinence medical
"a non-invasive solution for men living with urinary incontinence."
Urinary incontinence is the involuntary leakage of urine when a person cannot fully control their bladder, ranging from occasional dribbles to frequent, heavy leakage. For investors, it matters because it creates a steady, measurable market for treatments, devices, surgeries and home-care services—similar to a leaky pipe that needs repair or regular management—which can drive sales, influence clinical trial and regulatory risk, and affect health-care spending and reimbursement decisions.
male external catheter medical
"launched the Surity™ Male External Catheter, a non-invasive solution for men"
A male external catheter is a soft, flexible sheath that fits over the penis and channels urine into a collection bag without inserting anything into the body — similar to a wearable funnel or external sock for urine. Investors care because it is a non-invasive, consumable medical product used in hospitals and home care; demand, reimbursement rules, and infection-prevention advantages can affect recurring sales and healthcare cost dynamics.
urinary tract infections medical
"its association with urinary tract infections, dermatitis, slips and falls"
Urinary tract infections are bacterial infections of the body’s plumbing that includes the bladder, urethra and sometimes the kidneys, causing symptoms like painful urination, urgency and fever when more serious. They matter to investors because they are common, drive steady demand for treatments, diagnostics and prevention products, and can influence healthcare costs, regulatory attention and revenue prospects for companies developing drugs, tests or medical devices related to diagnosis and treatment.
meta-analysis medical
"Association of urinary incontinence and depression or anxiety: a meta‑analysis."
A meta-analysis combines results from multiple independent studies on the same question to produce a single, more reliable estimate of an effect or outcome. Like averaging many temperature readings to get a truer picture of the weather, it reduces random noise and highlights consistent signals; investors use it to assess how strong and reliable the scientific or economic evidence is, which affects regulatory outlook, product prospects, and valuation risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MÖLNDAL, Sweden, April 30, 2026 /PRNewswire/ -- Today, Wellspect HealthCare launched the Surity™ Male External Catheter, a non-invasive solution for men living with urinary incontinence. This builds on the company's expanding portfolio of reliable urinary incontinence management solutions in the U.S., following the introduction of the Surity™ Female External Catheter earlier this year, and ahead of the anticipated launch of the Surity™ Urinary Management System.

Severe urinary incontinence affects more than 13 million Americans and their caregivers, turning daily routines into ongoing challenges1. The condition can profoundly disrupt daily life and is often associated with sleep disturbances, increased risk of falls, dehydration, skin breakdown, and significant physical and emotional strain – for both patients and caregivers2-7.

Despite the availability of some management options today8,9, a substantial gap remains in providing effective, comfortable, and user-friendly solutions that can support the needs of men living with urinary incontinence.

The Surity™ Male External Catheter is a new non-invasive solution for men affected by urinary incontinence, suitable for use with compatible urine collection systems. By effectively diverting voided urine away from the body, Surity™ offers men and their caregivers a discreet, comfortable option in continence care. Developed with skin-friendly materials, it is suitable for up to 24 hours of wear and moves naturally with the body. Its distinctive features include a see-through design that supports easy placement and visual checks, a slim profile to reduce bulk, and a soft, non-woven backing material designed to be gentle on the skin.

"By expanding the Surity™ portfolio to include solutions for both men and women living with severe urinary incontinence, we aim to help address a clear gap in incontinence care," said Chris Schlenk, Group Vice President at Wellspect HealthCare. "Our goal is to offer solutions designed to support comfort, rest, and confidence for people facing these challenges each day."

Surity™ was created to address practical challenges related to dryness, comfort, dignity, and caregiver support within the urinary incontinence segment, reflecting Wellspect's commitment to improving quality of life for people managing continence care needs.

The launch of the Surity™ Male External Catheter builds on the positive feedback received for the Surity™ Female External Catheter, shared by women living with severe urinary incontinence and their caregivers. This feedback has highlighted ease of use, comfort, and fit.

"Surity™ has provided me with a practical option for my day-to-day life. It is easy to place and has integrated seamlessly into my routines, helping me feel confident in the management of my care," said Dru Woodward*, who uses the Surity™ Female External Catheter as part of her daily care routine.

Insights from these experiences continue to inform the evolution and expansion of the Surity™ portfolio.

The Surity™ Male External Catheter is now available for home purchase at www.surity.care and will soon be available to healthcare institutions.

Images available for download here

* This patient received compensation for sharing their experience

  1. Leslie SW, Tran LN, Puckett Y. Urinary incontinence. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. Updated 2024 Aug 11. Available from: https://www\.ncbi\.nlm\.nih\.gov/books/NBK559095/ 
  2. Duncan I, Stocking A, Fitzner K, Ahmed T, Huynh N. The prevalence of incontinence and its association with urinary tract infections, dermatitis, slips and falls, and behavioral disturbances among older adults in Medicare fee‑for‑service. J Wound Ostomy Continence Nurs. 2024 Mar–Apr;51(2):138‑45. 
  3. Appeadu MK, Bordoni B. Falls and fall prevention in older adults. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. Updated 2023 Jun 4. Available from: https://www\.ncbi\.nlm\.nih\.gov/books/NBK560761/ 
  4. Mayo Clinic Staff. Bladder control: lifestyle strategies ease problems. Mayo Clinic. 2025 May 10. Available from: https://www\.mayoclinic\.org/diseases\-conditions/urinary\-incontinence/in\-depth/bladder\-control\-problem/art\-20046597 
  5. National Association for Continence. The true impact of incontinence. NAFC; 2025. Available from: https://nafc\.org/bhealth\-blog/the\-true\-impact\-of\-incontinence/ 
  6. Cheng S, Lin D, Hu T, et al. Association of urinary incontinence and depression or anxiety: a meta‑analysis. J Int Med Res. 2020;48(6):0300060520931348. 
  7. Family Caregiver Alliance. Caring for someone with incontinence: emotional and social issues. Family Caregiver Alliance; 2014. Available from: https://www\.caregiver\.org/resource/caring\-someone\-incontinence\-emotional\-and\-social\-issues/ 
  8. Geng V, C‑B H, Lurvink H, Pearce I, Vahr S. Evidence‑based guidelines for best practice in urological health care: male external catheters in adults; urinary catheter management. Arnhem: EAUN; 2016. Available from: https://nurses\.uroweb\.org/wpcontent/uploads/EAUN16\_Guideline\_complete\_LR\.pdf 
  9. Newman DK, Wein AJ. External catheter collection systems. In: Newman DK, Wein AJ, editors. Clinical application of urologic catheters, devices and products. Cham: Springer Nature; 2018. p. 79‑103. 

For more details, please contact:

Marion Par-Weixlberger | Vice President Public Relations, Corporate Communications & Brand
publicrelations@dentsplysirona.com

About Wellspect HealthCare

Wellspect HealthCare, a subsidiary of Dentsply Sirona, is a leading global provider of innovative medical devices dedicated to improving the quality of life for individuals with bladder and bowel dysfunction.

With approximately 1,200 employees worldwide, Wellspect is committed to making a real difference for people managing continence care needs, empowering them to live each day to the fullest.

Wellspect delivers solutions that support safe bladder and bowel management, while continuously enhancing the experience, clinical performance, and service quality for both healthcare professionals and the people in their care.

As one of the world's leading manufacturers of intermittent urinary catheters, Wellspect has been at the forefront of innovation since 1983 with its LoFric® brand, which introduced the first hydrophilic-coated catheter.

Wellspect has also pioneered the development of Navina™, an innovative transanal irrigation system designed to support individuals living with chronic bowel disorders.

With advanced Surity™, Wellspect provides reliable urinary incontinence care designed to restore comfort, rest, and confidence for people living with severe urinary incontinence and for their caregivers.

Every day, Wellspect strives to maintain the highest quality standards while minimizing the environmental impact of its products.

Headquartered in Mölndal, Sweden, Wellspect operates in more than 40 countries, offering life-enhancing solutions to people around the world. Dentsply Sirona, the world's largest diversified manufacturer of professional dental products and technologies, is listed on Nasdaq under the symbol XRAY.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/wellspect-healthcare-expands-surity-portfolio-in-the-us-with-surity-male-external-catheter-for-urinary-incontinence-care-302758693.html

SOURCE Wellspect HealthCare

FAQ

When did Wellspect (XRAY) launch the Surity Male External Catheter in the U.S.?

Wellspect launched the Surity Male External Catheter in the U.S. on April 30, 2026. According to the company, the product complements the earlier Surity Female External Catheter and precedes the planned Surity Urinary Management System.

What are the key features of the Surity Male External Catheter from Wellspect (XRAY)?

The catheter is a non‑invasive, wearable device suitable for up to 24 hours and has a see‑through, slim design. According to the company, it uses skin‑friendly materials and is compatible with urine collection systems for discreet continence care.

Where can patients buy the Surity Male External Catheter from Wellspect (XRAY)?

The Surity Male External Catheter is available for home purchase at www.surity.care now. According to the company, availability to healthcare institutions will follow and is described as coming soon.

Does Wellspect (XRAY) provide clinical or pricing details for the Surity Male External Catheter?

The announcement does not include clinical outcome data or pricing information. According to the company, product features and user feedback informed the launch, but reimbursement and sales figures were not disclosed.